https://www.prnewswire.co.uk/news-releases/telix-at-eau-2022-focu...

https://www.prnewswire.co.uk/news-releases/telix-at-eau-2022-focus-on-psma-pet-imaging-889923158.html

MELBOURNE, Australia and LIÈGE, Belgium, June 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it will be participating in the 37th Annual European Association of Urology (EAU) Congress to be held in Amsterdam from 1-4 July.

Gallium-based prostate-specific membrane antigen (PSMA) imaging with positron emission tomography (PET) (PSMA-PET) will be a highlight of the meeting, with 11 abstracts being presented on 68Ga-PSMA-11, along with seven major sessions on renal cancer, including three on clear cell renal cell carcinoma (ccRCC), the tumour target in Telix's ZIRCON (imaging) and STARLITE (therapy) studies.

PSMA-PET has been implemented into major clinical guidelines in Europe[1] and the United States[2] and recent scientific publications reinforce that this new imaging modality is becoming established as a standard of care.[3],[4] The scientific community is now focusing on how PSMA-PET could improve the management of disease, and discussion at EAU will centre around the latest developments in prostate cancer imaging and how PSMA-PET imaging may support improved treatment decisions. This will be a focus of the Telix-sponsored symposium, The Influence of PSMA on Prostate Cancer Management, being held on Sunday, 3 July, 2022, at 17:45 CET.

Telix's investigational product TLX250-CDx for the imaging of ccRCC will also be presented by Dr. Robin Merkx of Radboud University in the Netherlands, in Abstract Session #53, Optimising treatment in locally advanced disease.

Telix Chief Medical Officer, Dr Colin Hayward said, "We are excited to be at EAU 2022, showcasing Telix's urologic oncology pipeline across prostate and kidney cancers at the first in-person EAU annual congress since 2019. It is particularly pleasing to see how the level of interest in PSMA-PET imaging for prostate cancer continues to grow, and we look forward to presenting Telix's sponsored symposium on the influence of PSMA on prostate cancer management."

EAU presentation details are as follows:

1. Sponsored Symposium: The Influence of PSMA on Prostate Cancer Management ("Get Onboard the PSMA Train").

A renowned panel of Nuclear Medicine thought leaders will explore how PSMA PET/CT may support better treatment decisions for patients;

- Chair and Speaker: Dr. Alicia Morgans, Genitourinary Medical Oncologist and Medical Director of the Survivorship Program at the Dana-Farber Cancer Institute in Boston (Massachusetts), U.S.A.
- Speaker: Dr. Jochen Christoph Walz, Professor in Urology and Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre in Marseille, France.
- Speaker: Dr. Stefano Fanti, Professor of Diagnostic Imaging and Director of the Nuclear Medicine Division and PET Unit at the S. Orsola Policlinic Hospital in Bologna, Italy.

The Telix sponsored symposium will also be available as a live-stream via the Congress Virtual Platform here: https://virtual.uroweb.org/virtual/eau22/access

2. Poster Presentation (Telix-supported): 89Zr-girentuximab positron emission tomography in clear cell renal cell carcinoma.

- Presenter: Dr. Robin Merkx, Radboud Universiteit, Nijmegen, Netherlands.
- Abstract Session 53: Optimising treatment in locally advanced disease.
- Poster ID: A0995.
- Date & Time: Monday, 4 July, 2022, 10:30 – 12:00 CET.

The Annual EAU Congress is Europe’s biggest urological event with specialists and affiliated medical professionals gathering for a critical assessment of clinical practices and key research developments.

https://eaucongress.uroweb.org/